New Data Presented from Across the Transthyretin Amyloidosis Franchise at the Heart Failure 2025 Congress

17 May, 2025 New Data Presented from Across the Transthyretin Amyloidosis Franchise at the Heart Failure 2025 Congress

The following presentations include the latest data from the HELIOS-B Phase 3 study and results from across the flagship transthyretin amyloidosis (TTR) franchise presented at Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology.

Fontana, et al. “Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial”

Morbach, et al. “Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-word Study in Five European Countries and Japan”

Bondue, et al. “Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program”

Fontana, et al. “Design and Rationale of a Phase 3 Study to Evaluate Efficacy and Safety of Nucresiran (ALN-TTRsc04) in Patients with Transthyretin Amyloidosis with Cardiomyopathy”

Gonzalez-Costello, et al. “Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis”